Kelsey E McLimans1, Auriel A Willette1,2,3,4. 1. Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, USA. 2. Department of Psychology, Iowa State University, Ames, IA, USA. 3. Department of Neurology, University of Iowa, Iowa City, IA, USA. 4. Aging Mind and Brain Initiative, University of Iowa, Iowa City, IA, USA.
Abstract
BACKGROUND: Obesity and insulin resistance are associated with neuropathology and cognitive decline in Alzheimer's disease (AD). OBJECTIVE: Ecto-nucleotide pyrophosphatase/phosphodiesterase 2, also called autotaxin, is produced by beige adipose tissue, regulates metabolism, and is higher in AD prefrontal cortex (PFC). Autotaxin may be a novel biomarker of dysmetabolism and AD. METHODS: We studied Alzheimer's Disease Neuroimaging Initiative participants who were cognitively normal (CN; n = 86) or had mild cognitive impairment (MCI; n = 135) or AD (n = 66). Statistical analyses were conducted using SPSS software. Multinomial regression analyses tested if higher autotaxin was associated with higher relative risk for MCI or AD diagnosis, compared to the CN group. Linear mixed model analyses were used to regress autotaxin against MRI, FDG-PET, and cognitive outcomes. Spearman correlations were used to associate autotaxin and CSF biomarkers due to non-normality. FreeSurfer 4.3 derived mean cortical thickness in medial temporal lobe and prefrontal regions of interest. RESULTS: Autotaxin levels were significantly higher in MCI and AD. Each point increase in log-based autotaxin corresponded to a 3.5 to 5 times higher likelihood of having MCI and AD, respectively. Higher autotaxin in AD predicted hypometabolism in the medial temporal lobe [R2 = 0.343, p < 0.001] and PFC [R2 = 0.294, p < 0.001], and worse performance on executive function and memory factors. Autotaxin was associated with less cortical thickness in PFC areas like orbitofrontal cortex [R2 = 0.272, p < 0.001], as well as levels of total tau, p-tau181, and total tau/Aβ1-42. CONCLUSIONS: These results are comparable to previous reports using insulin resistance. CSF autotaxin may be a useful dysmetabolism biomarker for examining AD outcomes and risk.
BACKGROUND:Obesity and insulin resistance are associated with neuropathology and cognitive decline in Alzheimer's disease (AD). OBJECTIVE:Ecto-nucleotide pyrophosphatase/phosphodiesterase 2, also called autotaxin, is produced by beige adipose tissue, regulates metabolism, and is higher in AD prefrontal cortex (PFC). Autotaxin may be a novel biomarker of dysmetabolism and AD. METHODS: We studied Alzheimer's Disease Neuroimaging Initiative participants who were cognitively normal (CN; n = 86) or had mild cognitive impairment (MCI; n = 135) or AD (n = 66). Statistical analyses were conducted using SPSS software. Multinomial regression analyses tested if higher autotaxin was associated with higher relative risk for MCI or AD diagnosis, compared to the CN group. Linear mixed model analyses were used to regress autotaxin against MRI, FDG-PET, and cognitive outcomes. Spearman correlations were used to associate autotaxin and CSF biomarkers due to non-normality. FreeSurfer 4.3 derived mean cortical thickness in medial temporal lobe and prefrontal regions of interest. RESULTS:Autotaxin levels were significantly higher in MCI and AD. Each point increase in log-based autotaxin corresponded to a 3.5 to 5 times higher likelihood of having MCI and AD, respectively. Higher autotaxin in AD predicted hypometabolism in the medial temporal lobe [R2 = 0.343, p < 0.001] and PFC [R2 = 0.294, p < 0.001], and worse performance on executive function and memory factors. Autotaxin was associated with less cortical thickness in PFC areas like orbitofrontal cortex [R2 = 0.272, p < 0.001], as well as levels of total tau, p-tau181, and total tau/Aβ1-42. CONCLUSIONS: These results are comparable to previous reports using insulin resistance. CSF autotaxin may be a useful dysmetabolism biomarker for examining AD outcomes and risk.
Authors: Rachel Galioto; Michael L Alosco; Mary Beth Spitznagel; Gladys Strain; Michael Devlin; Ronald Cohen; Ross D Crosby; James E Mitchell; John Gunstad Journal: J Clin Exp Neuropsychol Date: 2015-04-15 Impact factor: 2.475
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Michal Figurski; Els Coart; Kaj Blennow; Holly Soares; Adam J Simon; Piotr Lewczuk; Robert A Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2011-02-11 Impact factor: 17.088
Authors: Auriel A Willette; Barbara B Bendlin; Erika J Starks; Alex C Birdsill; Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Asenath La Rue; Bruce P Hermann; Rebecca L Koscik; Erin M Jonaitis; Mark A Sager; Sanjay Asthana Journal: JAMA Neurol Date: 2015-09 Impact factor: 18.302
Authors: Zsuzsanna Tucsek; Peter Toth; Danuta Sosnowska; Tripti Gautam; Matthew Mitschelen; Akos Koller; Gabor Szalai; William E Sonntag; Zoltan Ungvari; Anna Csiszar Journal: J Gerontol A Biol Sci Med Sci Date: 2013-11-22 Impact factor: 6.053
Authors: Auriel A Willette; Barbara B Bendlin; Ricki J Colman; Erik K Kastman; Aaron S Field; Andrew L Alexander; Aadhavi Sridharan; David B Allison; Rozalyn Anderson; Mary-Lou Voytko; Joseph W Kemnitz; Richard H Weindruch; Sterling C Johnson Journal: Diabetes Date: 2012-03-13 Impact factor: 9.461
Authors: Auriel A Willette; Guofan Xu; Sterling C Johnson; Alex C Birdsill; Erin M Jonaitis; Mark A Sager; Bruce P Hermann; Asenath La Rue; Sanjay Asthana; Barbara B Bendlin Journal: Diabetes Care Date: 2012-10-15 Impact factor: 19.112
Authors: Hugh C Hendrie; Mengjie Zheng; Kathleen A Lane; Roberta Ambuehl; Christianna Purnell; Shanshan Li; Frederick W Unverzagt; Michael D Murray; Ashok Balasubramanyam; Chris M Callahan; Sujuan Gao Journal: Alzheimers Dement Date: 2018-04-18 Impact factor: 21.566
Authors: Roman Dario Moreno-Fernandez; Sara Tabbai; Estela Castilla-Ortega; Margarita Perez-Martin; Guillermo Estivill-Torrus; Fernando Rodriguez de Fonseca; Luis Javier Santin; Carmen Pedraza Journal: Curr Neuropharmacol Date: 2018-03-05 Impact factor: 7.363